Loading...
Loading...
BDTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.8M |
| Gross Profit | -0.8M |
| Operating Expense | 21.6M |
| Operating I/L | -21.6M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.6M |
| Pretax | -20.9M |
| Income Tax Expense | -0.7M |
| Net Income/Loss | -20.2M |
Black Diamond Therapeutics, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of medicines for patients with genetically defined tumors. The company's primary focus is on developing innovative small molecule inhibitors, including BDTX-189 targeting non-canonical EGFR and HER2 mutations, BDTX-1535 for various EGFR mutations, and BDTX-4933 for BRAF alterations. These products are designed to address specific genetic tumor profiles, offering potential therapeutic solutions. Additionally, the company has a strategic partnership with OpenEye Scientific Software, Inc., enhancing its research and development capabilities.
